Meanwhile, the company s earnings before interest, taxes, depreciation and amortization (EBITDA) came in at Rs 320.5 crore, up from Rs 297 crore in the year-ago period.
Gland Pharma share price: The counter's 14-day relative strength index (RSI) came at 16.61. A level below 30 is defined as oversold while a value above 70 is considered overbought. The company's stock has a price-to-equity (P/E) ratio of 22.73. It has a price-to-book (P/B) value of 2.22.
Gland Pharma share price: The counter's 14-day relative strength index (RSI) came at 70.61. A level below 30 is defined as oversold while a value above 70 is considered overbought. The company's stock has a price-to-equity (P/E) ratio of 20.64. It has a price-to-book (P/B) value of 2.65.
Read more about After 100% gain since Nov, can the rally in Gland Pharma stock continue? on Business Standard. Gland s prospects remain strong, say analysts, as it has a robust pipeline of products with 50 pending Abbreviated New Drug Applications (ANDAs) and a healthy filing rate of 21 ANDAs in 9MFY21